User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium

Primary tabs

download
  • Open access
  • PDF
  • 889.17 K
Degré, Delphine Sersté, Thomas Lasser, Luc Delwaide, Jean Starkel, Peter [UCL] Jhaveri, Ravi

Introduction Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens. Most trials have been conducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus simeprevir in a real-world cohort of HCV GT4 patients with advanced fibrosis. Patients and Methods Eighty-seven GT4 treatment-naïve or –Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Results Patients were 51.7% male, 78.2% IFN/RBV treatment-experienced, and 37.9% received RBV treatment. The overall sustained virologic response at least 12 weeks after treatment (SVR12) rate was 87.4% while patients treated with and without RBV had rates of 87.9% and 87% (p = 0.593), respectively, and patients with advanced fibrosis (F3) and patients with cirrhosis had SVR12 rates of 94.4% and 82.4% (p = 0.087), respectively. SVR12 rates in treatment-naïve patients and in IFN/RBV -experienced patients were 78.9% and 89.7% (p = 0.191), respectively. Treatment failure occurred most commonly in patients with cirrhosis and severe disease. The treatment was well tolerated and no patient died or discontinued treatment due to adverse events. Conclusions Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated. RBV did not appear to increase the rate of SVR12.

Document type Article de périodique (Journal article)
Access type Accès libre
Publication date 2017
Language Anglais
Journal information "PLOS ONE" - Vol. 12, no.1, p. e0170933 (2017)
Peer reviewed yes
Publisher Public Library of Science (PLoS)
e-issn 1932-6203
Publication status Publié
Affiliations UCL - (SLuc) Service d'hépato-gastro-entérologie
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
Links
  1. Mohd Hanafiah Khayriyyah, Groeger Justina, Flaxman Abraham D., Wiersma Steven T., Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence, 10.1002/hep.26141
  2. Wise Matthew, Bialek Stephanie, Finelli Lyn, Bell Beth P., Sorvillo Frank, Changing trends in hepatitis C-related mortality in the United States, 1995-2004, 10.1002/hep.22165
  3. Ghany Marc G., Strader Doris B., Thomas David L., Seeff Leonard B., Diagnosis, management, and treatment of hepatitis C: An update, 10.1002/hep.22759
  4. Backus Lisa I., Boothroyd Derek B., Phillips Barbara R., Belperio Pamela, Halloran James, Mole Larry A., A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C, 10.1016/j.cgh.2011.03.004
  5. van der Meer Adriaan J., Veldt Bart J., Feld Jordan J., Wedemeyer Heiner, Dufour Jean-François, Lammert Frank, Duarte-Rojo Andres, Heathcote E. Jenny, Manns Michael P., Kuske Lorenz, Zeuzem Stefan, Hofmann W. Peter, de Knegt Robert J., Hansen Bettina E., Janssen Harry L. A., Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis, 10.1001/jama.2012.144878
  6. Afdhal Nezam, Reddy K. Rajender, Nelson David R., Lawitz Eric, Gordon Stuart C., Schiff Eugene, Nahass Ronald, Ghalib Reem, Gitlin Norman, Herring Robert, Lalezari Jacob, Younes Ziad H., Pockros Paul J., Di Bisceglie Adrian M., Arora Sanjeev, Subramanian G. Mani, Zhu Yanni, Dvory-Sobol Hadas, Yang Jenny C., Pang Phillip S., Symonds William T., McHutchison John G., Muir Andrew J., Sulkowski Mark, Kwo Paul, Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection, 10.1056/nejmoa1316366
  7. Afdhal Nezam, Zeuzem Stefan, Kwo Paul, Chojkier Mario, Gitlin Norman, Puoti Massimo, Romero-Gomez Manuel, Zarski Jean-Pierre, Agarwal Kosh, Buggisch Peter, Foster Graham R., Bräu Norbert, Buti Maria, Jacobson Ira M., Subramanian G. Mani, Ding Xiao, Mo Hongmei, Yang Jenny C., Pang Phillip S., Symonds William T., McHutchison John G., Muir Andrew J., Mangia Alessandra, Marcellin Patrick, Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, 10.1056/nejmoa1402454
  8. Feld Jordan J., Kowdley Kris V., Coakley Eoin, Sigal Samuel, Nelson David R., Crawford Darrell, Weiland Ola, Aguilar Humberto, Xiong Junyuan, Pilot-Matias Tami, DaSilva-Tillmann Barbara, Larsen Lois, Podsadecki Thomas, Bernstein Barry, Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin, 10.1056/nejmoa1315722
  9. Kowdley Kris V., Gordon Stuart C., Reddy K. Rajender, Rossaro Lorenzo, Bernstein David E., Lawitz Eric, Shiffman Mitchell L., Schiff Eugene, Ghalib Reem, Ryan Michael, Rustgi Vinod, Chojkier Mario, Herring Robert, Di Bisceglie Adrian M., Pockros Paul J., Subramanian G. Mani, An Di, Svarovskaia Evguenia, Hyland Robert H., Pang Phillip S., Symonds William T., McHutchison John G., Muir Andrew J., Pound David, Fried Michael W., Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis, 10.1056/nejmoa1402355
  10. Zeuzem Stefan, Jacobson Ira M., Baykal Tolga, Marinho Rui T., Poordad Fred, Bourlière Marc, Sulkowski Mark S., Wedemeyer Heiner, Tam Edward, Desmond Paul, Jensen Donald M., Di Bisceglie Adrian M., Varunok Peter, Hassanein Tarek, Xiong Junyuan, Pilot-Matias Tami, DaSilva-Tillmann Barbara, Larsen Lois, Podsadecki Thomas, Bernstein Barry, Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin, 10.1056/nejmoa1401561
  11. Lawitz Eric, Sulkowski Mark S, Ghalib Reem, Rodriguez-Torres Maribel, Younossi Zobair M, Corregidor Ana, DeJesus Edwin, Pearlman Brian, Rabinovitz Mordechai, Gitlin Norman, Lim Joseph K, Pockros Paul J, Scott John D, Fevery Bart, Lambrecht Tom, Ouwerkerk-Mahadevan Sivi, Callewaert Katleen, Symonds William T, Picchio Gaston, Lindsay Karen L, Beumont Maria, Jacobson Ira M, Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study, 10.1016/s0140-6736(14)61036-9
  12. EASL Recommendations on Treatment of Hepatitis C 2015, 10.1016/j.jhep.2015.03.025
  13. , Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus : HEPATITIS C VIRUS GUIDANCE PANEL, 10.1002/hep.27950
  14. P Kwo, Hepatology (2016)
  15. Sulkowski Mark S., Vargas Hugo E., Di Bisceglie Adrian M., Kuo Alexander, Reddy K. Rajender, Lim Joseph K., Morelli Giuseppe, Darling Jama M., Feld Jordan J., Brown Robert S., Frazier Lynn M., Stewart Thomas G., Fried Michael W., Nelson David R., Jacobson Ira M., Afdhal N., Alam I., Ben-Ari Z., Bredfeldt J., Brown R.S., Chung R.T., Darling J., Harlan W., Di Bisceglie A.M., Dickson R.C., Elbeshbeshy H.A., Everson G., Feld J., Fenkel J.M., Fried M.W., Galati J., Gordon S.C., Hassan M., Hawkins T.N., Hinestrosa F., Jacobson I.M., Kerr C.A., Kuo A., Kwo P.Y., Levitsky J., Lim J., Lok A.S., Mailliard M., Manns M.P., Morelli G., Muir A.J., Nelson D., O’Leary J.G., Pearlman B.L., Pockros P., Ramani A., Reau N., Reddy K.R., Schiff E.R., Sherman K.E., Shiffman M.L., Smith C., Spivey J.R., Sterling R.K., Sulkowski M.S., Szabo G., Terrault N.A., Trautwein C., Vargas H.E., Watts K., Williams A., Zeuzem S., Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection, 10.1053/j.gastro.2015.10.013
  16. Aqel Bashar A., Pungpapong Surakit, Leise Michael, Werner K. Tuesday, Chervenak Amy E., Watt Kymberly D., Murphy Jennifer L., Ryland Kristen, Keaveny Andrew P., McLemore Ryan, Vargas Hugo E., Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis : HEPATOLOGY, Vol. XX, No. X, 2015 AQEL ET AL., 10.1002/hep.27937
  17. Wantuck J. M., Ahmed A., Nguyen M. H., Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6, 10.1111/apt.12551
  18. Kamal Sanaa M., Nasser Imad A., Hepatitis C genotype 4: What we know and what we don't yet know, 10.1002/hep.22127
  19. Nicot F., Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France, 10.1099/vir.0.80409-0
  20. Kamal Sanaa M., Hepatitis C genotype 4 therapy: increasing options and improving outcomes, 10.1111/j.1478-3231.2008.01930.x
  21. Khattab Mahmoud A., Ferenci Peter, Hadziyannis Stephanos J., Colombo Massimo, Manns Michael P., Almasio Piero L., Esteban Rafael, Abdo Ayman A., Harrison Stephen A., Ibrahim Nazir, Cacoub Patrice, Eslam Mohammed, Lee Samuel S., Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel, 10.1016/j.jhep.2010.11.016
  22. Ray Stuart C., Arthur Ray R., Carella Anthony, Bukh Jens, Thomas David L., Genetic Epidemiology of Hepatitis C Virus throughout Egypt, 10.1086/315786
  23. Khan MohammedQ, Al-Ahdal Mohammed, Al Thawadi Sahar, Helmy AhmadSalem, Al Qahtani Ahmed, Sanai FaisalM, Al Ashgar HamadI, Hepatitis C genotype 4: Genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia, 10.4103/1319-3767.105920
  24. Lawitz Eric, Mangia Alessandra, Wyles David, Rodriguez-Torres Maribel, Hassanein Tarek, Gordon Stuart C., Schultz Michael, Davis Mitchell N., Kayali Zeid, Reddy K. Rajender, Jacobson Ira M., Kowdley Kris V., Nyberg Lisa, Subramanian G. Mani, Hyland Robert H., Arterburn Sarah, Jiang Deyuan, McNally John, Brainard Diana, Symonds William T., McHutchison John G., Sheikh Aasim M., Younossi Zobair, Gane Edward J., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, 10.1056/nejmoa1214853
  25. Wehmeyer Malte H., Jordan Sabine, Lüth Stefan, Hartl Johannes, Stoehr Albrecht, Eißing Christiane, Lohse Ansgar W., Petersen Jörg, Buggisch Peter, Schulze zur Wiesch Julian, Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection, 10.1016/j.dld.2015.05.018
  26. Moreno Christophe, Hezode Christophe, Marcellin Patrick, Bourgeois Stefan, Francque Sven, Samuel Didier, Zoulim Fabien, Grange Jean-Didier, Shukla Umesh, Lenz Oliver, Ouwerkerk-Mahadevan Sivi, Fevery Bart, Peeters Monika, Beumont Maria, Jessner Wolfgang, Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4, 10.1016/j.jhep.2014.12.031
  27. Castéra Laurent, Vergniol Julien, Foucher Juliette, Le Bail Brigitte, Chanteloup Elise, Haaser Maud, Darriet Monique, Couzigou Patrice, de Lédinghen Victor, Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C, 10.1053/j.gastro.2004.11.018
  28. Ferraioli Giovanna, Tinelli Carmine, Dal Bello Barbara, Zicchetti Mabel, Filice Gaetano, Filice Carlo, , Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study, 10.1002/hep.25936
  29. Holmberg S. D., Lu M., Rupp L. B., Lamerato L. E., Moorman A. C., Vijayadeva V., Boscarino J. A., Henkle E. M., Gordon S. C., Holmberg S. D., Teshale E. H., Spradling P. R., Moorman A. C., Gordon S. C., Nerenz D. R., Lu M., Lamerato L., Rupp L. B., Akkerman N., Oja-Tebbe N. J., Cogan C. M., Larkin D., Boscarino J. A., Daar Z. S., Smith R. E., Curry P. J., Geise B. D., Leader J. B., Nakasato C. C., Vijayadeva V., Sylva K. E., Parker J. V., Schmidt M. M., Henkle E. M., Dodge T. L., Keast E. M., Drew L., , Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort, 10.1093/cid/cit245
  30. Belgian HCV therapy guidance. Belgian Association for the Study of the Liver BASL. http://www.basl.be
  31. Lawitz Eric, Matusow Gary, DeJesus Edwin, Yoshida Eric M., Felizarta Franco, Ghalib Reem, Godofsky Eliot, Herring Robert W., Poleynard Gary, Sheikh Aasim, Tobias Hillel, Kugelmas Marcelo, Kalmeijer Ronald, Peeters Monika, Lenz Oliver, Fevery Bart, De La Rosa Guy, Scott Jane, Sinha Rekha, Witek James, Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2) : Lawitz et al., 10.1002/hep.28422
  32. Doss Wahid, Shiha Gamal, Hassany Mohamed, Soliman Reham, Fouad Rabab, Khairy Marwa, Samir Waleed, Hammad Radi, Kersey Kathryn, Jiang Deyuan, Doehle Brian, Knox Steven J., Massetto Benedetta, McHutchison John G., Esmat Gamal, Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4, 10.1016/j.jhep.2015.04.023
  33. Willemse S. B., Baak L. C., Kuiken S. D., van der Sluys Veer A., Lettinga K. D., van der Meer J. T. M., Depla A. C. T. M., Tuynman H., van Nieuwkerk C. M. J., Schinkel C. J., Kwa D., Reesink H. W., van der Valk M., Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life, 10.1111/jvh.12567
  34. Kohli Anita, Kapoor Rama, Sims Zayani, Nelson Amy, Sidharthan Sreetha, Lam Brian, Silk Rachel, Kotb Colleen, Gross Chloe, Teferi Gebeyehu, Sugarman Kate, Pang Phillip S, Osinusi Anu, Polis Michael A, Rustgi Vinod, Masur Henry, Kottilil Shyam, Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study, 10.1016/s1473-3099(15)00157-7
  35. Manns Michael, Samuel Didier, Gane Edward J, Mutimer David, McCaughan Geoff, Buti Maria, Prieto Martín, Calleja José Luis, Peck-Radosavljevic Markus, Müllhaupt Beat, Agarwal Kosh, Angus Peter, Yoshida Eric M, Colombo Massimo, Rizzetto Mario, Dvory-Sobol Hadas, Denning Jill, Arterburn Sarah, Pang Phillip S, Brainard Diana, McHutchison John G, Dufour Jean-François, Van Vlierberghe Hans, van Hoek Bart, Forns Xavier, Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial, 10.1016/s1473-3099(16)00052-9
  36. Zeuzem Stefan, Ghalib Reem, Reddy K. Rajender, Pockros Paul J., Ari Ziv Ben, Zhao Yue, Brown Deborah D., Wan Shuyan, DiNubile Mark J., Nguyen Bach-Yen, Robertson Michael N., Wahl Janice, Barr Eliav, Butterton Joan R., Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection : A Randomized Trial, 10.7326/m15-0785
  37. T Asselah, Hepatology, 340A (2015)
  38. Feld Jordan J., Jacobson Ira M., Hézode Christophe, Asselah Tarik, Ruane Peter J., Gruener Norbert, Abergel Armand, Mangia Alessandra, Lai Ching-Lung, Chan Henry L.Y., Mazzotta Francesco, Moreno Christophe, Yoshida Eric, Shafran Stephen D., Towner William J., Tran Tram T., McNally John, Osinusi Anu, Svarovskaia Evguenia, Zhu Yanni, Brainard Diana M., McHutchison John G., Agarwal Kosh, Zeuzem Stefan, Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection, 10.1056/nejmoa1512610
  39. Curry Michael P., O’Leary Jacqueline G., Bzowej Natalie, Muir Andrew J., Korenblat Kevin M., Fenkel Jonathan M., Reddy K. Rajender, Lawitz Eric, Flamm Steven L., Schiano Thomas, Teperman Lewis, Fontana Robert, Schiff Eugene, Fried Michael, Doehle Brian, An Di, McNally John, Osinusi Anu, Brainard Diana M., McHutchison John G., Brown Robert S., Charlton Michael, Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis, 10.1056/nejmoa1512614
  40. Asselah Tarik, Hézode Christophe, Qaqish Roula B, ElKhashab Magdy, Hassanein Tarek, Papatheodoridis George, Feld Jordan J, Moreno Christophe, Zeuzem Stefan, Ferenci Peter, Yu Yao, Redman Rebecca, Pilot-Matias Tami, Mobashery Niloufar, Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial, 10.1016/s2468-1253(16)30001-2
  41. Food and Drug Administration (FDA). Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie, 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634. Accessed 8 February 2016.
Bibliographic reference Degré, Delphine ; Sersté, Thomas ; Lasser, Luc ; Delwaide, Jean ; Starkel, Peter ; et. al. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. In: PLOS ONE, Vol. 12, no.1, p. e0170933 (2017)
Permanent URL http://hdl.handle.net/2078.1/220322